Considering the genetic profile similarity between CoM and CM, especially those harbouring a BRAF mutation, targeted treatment with BRAF/MEK inhibitors, as employed in CM, could be considered. This evidence concerns the gene MAP2K7 and cutaneous mastocytosis.